BLAINTRAVESICALSOLUTION
Approved
Apr 2024
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
5/8 — Partial
ANKTIVA (nogapendekin alfa inbakicept-pmln) by Immunitas Therapeutics is inbakicept-pmln is an il-15 receptor agonist. First approved in 2024.
Drug data last refreshed 12h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ANKTIVA (nogapendekin alfa inbakicept-pmln) is an IL-15 receptor agonist administered intravesically for bladder cancer. It activates NK cells, CD8 T cells, and memory T cells without stimulating immunosuppressive Treg cells, enhancing anti-tumor immunity. In preclinical models, it demonstrated superior anti-tumor activity when combined with BCG compared to BCG alone.
Growth
Early-stage growth product with 46 linked roles; newly approved status indicates active commercial team building and expansion potential.
Mechanism of Action
inbakicept-pmln is an IL-15 receptor agonist. IL-15 signals through a heterotrimeric receptor that is composed of the common gamma chain (γc) subunit, the beta chain (βc) subunit, and the IL-15-specific alpha subunit, IL-15 receptor α. IL-15 is trans -presented by the IL-15 receptor α to the shared…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
ANKTIVA Plus BCG Versus BCG Monotherapy In Participants With BCG-Naïve/BCG-Exposed High-Grade Non-Muscle Invasive Papillary Bladder Cancer
Started May 2026
0NMIBC
A Study to Assess Anktiva in Patients With Long Covid-19.
Started Nov 2025
20 enrolled
Long COVID
A Study to Examine Anktiva for the Treatment of COVID-19.
Started Sep 2025
40 enrolled
Long COVIDLong COVID SyndromeLong Covid 19
Worked on ANKTIVA at Immunitas Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.